Article

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitors

2023-11-24

Abstract excerpt

<h4>Background: </h4> Tyrosine kinase inhibitors (TKIs) have altered the therapeutic landscape of multiple hematological and solid malignancies. FDA approved starting doses of TKIs are based on the recommended phase 2 dose (RP2D) in clinical trials. However, patients are started on lower doses in practice. We assessed the dosing, drug reduction rates, and drug discontinuation rates among FDA approved TKIs and ob...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cdb11473-531b-5308-88ac-52071dd31536
DOI: 10.12688/f1000research.124601.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitorsDOI 10.12688/f1000research.124601.1Read

Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi ArabiaSemantic proximity Read

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in ChinaSemantic proximity Read

Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF -mutated melanoma patients in the United States.Semantic proximity Read

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read

Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)Semantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Discontinuation Risk from Adverse Events: Immunotherapy Alone vs. Combined with Chemotherapy: A Systematic Review and Network Meta-analysisSemantic proximity Read

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveSemantic proximity Read

New Serious Safety Warnings of Targeted Anticancer Agents After Their Initial FDA ApprovalSemantic proximity Read

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical ImplicationsSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Tolerance to oral anticancer agent treatment in older adults with cancer: A secondary analysis of data from EHRs and a pilot study of patient-reported outcomesSemantic proximity Read